Indication and Clinical Use:

Fucibet® (fusidic acid and betamethasone valerate) is indicated for the topical treatment of eczematous dermatoses including atopic eczema, discoid eczema, stasis eczema and seborrhoeic eczema when secondary bacterial infection caused by Staphylococcus aureus is confirmed or suspected.

Fucibet® is suitable in cases where treatment with a potent corticosteroid is appropriate to manage the pruritus and inflammation associated with eczematous dermatoses, and is intended for use during flare-ups for short-term (up to 2 weeks) treatment against bacteria susceptible to fusidic acid.

To reduce the development of drug-resistant bacteria, Fucibet® should only be used to treat infections that are proven or strongly suspected to be caused by bacteria.

Safety and efficacy have been established in patients ≥6 years old. Use with caution in pediatric patients.

Contraindications:

● Systemic fungal infections
● Primary skin infections caused by fungi, virus or bacteria
● Skin eruptions associated with tuberculosis or syphilis
● Perioral dermatitis and rosacea
● Eruptions following vaccinations

Relevant warnings and precautions:

● Avoid long-term continuous use
● Risk of systemic absorption
● Should not be used under occlusive dressing, over extensive areas, or on the face, scalp, axillae or scrotum
● Risk of HPA-axis suppression; Cushing’s syndrome, hyperglycemia, and glycosuria
● Susceptibility to infections
● Use with care near eyes
● Risk of bacterial resistance or microbial overgrowth
● Skin atrophy
● Safety during pregnancy or lactation has not been established

For more information:

Please consult the Product Monograph at https://health-products.canada.ca/dpd-bdpp/index-eng.jsp for important information relating to adverse reactions, drug interactions, and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling LEO Pharma Medical Information at 1-800-263-4218.

© 2020 LEO Pharma Inc. All rights reserved.
® Registered trademark of LEO Pharma A/S used under license and distributed by LEO Pharma Inc.
www.leo-pharma.ca

Reference:

  1. Current Fucibet® Product Monograph, LEO Pharma Inc.